Do you mean the Wilson’s report that valued NEU on an unrisked basis at just over $100/share?
This assumed the 4 orphan syndrome’s currently under P2 were successful in P3 trials.
Do you mean the Wilson’s report that valued NEU on an unrisked...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
-0.200(1.06%) |
Mkt cap ! $2.381B | |||
| Open | High | Low | Value | Volume |
| $18.85 | $18.92 | $18.35 | $10.53M | 566.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45 | $18.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.73 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.73 |
Change
-0.200 ( 0.73 %) |
||||
| Open | High | Low | Volume | ||
| $18.89 | $18.89 | $18.36 | 91292 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| NEU (ASX) Chart |